SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Charter)
(State or Other Jurisdiction
|(Commission File Number)|
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading symbol(s)||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 3, 2022, Nektar Therapeutics, a Delaware corporation (“Nektar”), issued a press release (the “Press Release”) announcing its financial results for the quarter ended September 30, 2022. A copy of the Press Release is furnished herewith as Exhibit 99.1.
On October 25, 2022, Nektar announced that it would hold a webcast conference call on November 3, 2022 to review its financial results for the quarter ended September 30, 2022. This conference call is accessible through a link that is posted on the Home Page and Investors section of the Nektar website: http://ir.nektar.com.
Item 9.01 Financial Statements and Exhibits.
|99.1||Press release titled “Nektar Therapeutics Reports Third Quarter 2022 Financial Results” issued by Nektar Therapeutics on November 3, 2022.|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document).|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 3, 2022||By:||/s/ Mark A. Wilson|
|Mark A. Wilson|
|Chief Legal Officer and Secretary|
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
SAN FRANCISCO, Nov. 3, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2022.
Cash and investments in marketable securities on September 30, 2022, were approximately $546.4 million as compared to $628.2 million at the end of the second quarter of 2022. Our cash and marketable securities are expected to support our strategic development activities and operations through the middle of 2025.
“In the third quarter, we made progress advancing our biologics pipeline in oncology and immunology,” said Howard W. Robin, President and CEO of Nektar. “With our partner, Eli Lilly, we presented positive proof-of-concept data for NKTR-358 in atopic dermatitis which demonstrate the potential for this first-in-class Treg stimulator to emerge as a differentiated therapy for patients with serious inflammatory conditions. In the first half of 2023, we expect Lilly to report topline data from the Phase 2 study of NKTR-358 in lupus as well as initiate a Phase 2 study in atopic dermatitis.”
“In addition, we are also advancing NKTR-255 in large B-cell lymphoma, with plans to launch a comparative study in combination with approved autologous CD19 CAR-T therapies,” continued Robin. “NKTR-255 targets the IL-15 pathway and we have conducted and published extensive preclinical studies showing that IL-15 can potentiate these approved cell therapies by expanding and extending the persistence of CAR-T cells. Finally, we are planning presentations at both SITC and ASH for both our preclinical and clinical programs that will showcase the strength of our science and lay the foundation for continued pipeline progress.”
Summary of Financial Results
Revenue, which primarily includes non-cash royalty revenue, in the third quarter of 2022 was $23.6 million as compared to $24.9 million in the third quarter of 2021. Revenue for the first nine months of 2022 was $70.0 million as compared to $76.9 million in the first nine months of 2021. Revenue was lower compared to 2021 as a result of a decrease in non-cash royalty revenue.
Total operating costs and expenses in the third quarter of 2022 were $77.9 million as compared to $138.5 million in the third quarter of 2021. Total operating costs and expenses in the first nine months of 2022 were $393.7 million as compared to $410.1 million in the first nine months of 2021. Operating costs and expenses for the first nine months of 2022 include $124.3 million in restructuring, impairment and other costs of terminated program.
R&D expense in the third quarter of 2022 was $33.6 million as compared to $103.7 million for the third quarter of 2021. For the first nine months of 2022, R&D expense was $183.6 million as compared to $300.7 million in the first nine months of 2021. R&D expense decreased for both the third quarter and the first nine months of 2022 primarily due to the wind down of the bempegaldesleukin program.
G&A expense was $22.5 million in the third quarter of 2022 and $29.5 million in the third quarter of 2021. For the first nine months of 2022, G&A expense was $70.4 million as compared to $90.7 million in the first nine months of 2021. G&A expense decreased for both the third quarter and the first nine months of 2022 primarily due to the wind down of the bempegaldesleukin program.
Restructuring, impairment and other costs of terminated program was $16.8 million in the third quarter of 2022 and $124.3 million in the first nine months of 2022. The year-to-date amount includes $58.5 million in non-cash lease and equipment impairment charges, $29.8 million in employee severance expense and $28.9 million for clinical trial and related employee compensation costs for the wind down of the bempegaldesleukin program, as well as $7.1 million in other restructuring costs.
Net loss for the third quarter of 2022 was $59.0 million or $0.31 basic and diluted loss per share as compared to a net loss of $129.7 million or $0.70 basic and diluted loss per share in the third quarter of 2021. Net loss in the first nine months of 2022 was $308.5 million or $1.65 basic and diluted loss per share as compared to a net loss of $378.2 million or $2.07 basic and diluted loss per share in the first nine months of 2021.
Third Quarter 2022 and Recent Business Highlights:
|●||In September 2022, Nektar presented data from two Phase 1b proof-of-concept studies of rezpegaldesleukin in patients with atopic dermatitis (AD) and plaque psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) Congress. Data from both studies showed rezpegaldesleukin’s ability to stimulate Tregs to target an immune system imbalance resulting in an improvement of disease activity in patients. Particularly in AD patients, dose-dependent improvements in key efficacy measures including EASI and vIGA-AD scores were observed for an additional 36 weeks following the 12-week treatment period.|
|●||In August 2022, Nektar announced the publication of preclinical data for NKTR-255 in Blood Advances, the open-access journal of the American Society of Hematology. The data highlighted the effects of NKTR-255 on natural killer cell function and proliferation in multiple myeloma (MM), supporting the clinical development of NKTR-255 and further evaluation of the novel immunotherapeutic approach in MM, alone or in combination with monoclonal antibodies or potentially with other immunomodulatory drugs.|
Nektar also announced upcoming presentations at the following scientific congresses:
The Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 8-12, 2022 (In person and virtual)
|●||Poster presentation: “NKTR-288, a polymer-conjugated interferon gamma mutein for the treatment of solid tumors”, Hamel, D., et al.|
|●||Poster presentation (Trials in Progress): “JAVELIN Bladder Medley: a phase 2 trial of avelumab in combination with other antitumor drugs as first-line maintenance therapy for advanced urothelial carcinoma”, Hoffman-Censits, J., et al. (collaborator presentation with Merck KGaA)|
2022 American Society of Hematology (ASH) Annual Meeting
December 10-13, 2022 (In person and virtual)
|●||Poster presentation: “Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies”, Patel K., et al.|
|●||Poster presentation (Trials in Progress): “A Phase 2/3, Randomized, Double Blind, Placebo-Controlled, Multicenter Study of NKTR-255 Vs Placebo Following CD-19 Directed CAR-T Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma”, Perales M., et al.|
Conference Call to Discuss Third Quarter 2022 Financial Results
Nektar management will host a conference call to review the results beginning at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time, November 3, 2022.
This press release and a live audio-only webcast of the conference call can be accessed through a link that is posted on the home page and Investors section of the Nektar website: https://ir.nektar.com/. The web broadcast of the conference call will be available for replay through December 3, 2022.
To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.
In the event that any non-GAAP financial measure is discussed on the conference call that is not described in this press release, or explained on the conference call, related information will be made available on the Investors section of the Nektar website as soon as practical after the conclusion of the conference call.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology and immunology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements which can be identified by words such as: “will,” “may,” “expect,” “potential,” “advance,” “initiate” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the therapeutic potential of, and future development plans for rezpegaldesleukin (previously referred to as NKTR-358), NKTR-255 and our other drug candidates in research programs, the prospects and plans for our collaborations with other companies, the timing of the initiation of clinical studies and the data readouts for our drug candidates, and our expectations (including our expected charges and cost savings) following our corporate restructuring, reorganization and workforce reduction, and our expected working capital and our cash runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results to differ materially from those indicated in the forward-looking statements include, among others: (i) our statements regarding the therapeutic potential of rezpegaldesleukin, NKTR-255 and our other drug candidates are based on preclinical and clinical findings and observations and are subject to change as research and development continue; (ii) rezpegaldesleukin, NKTR-255 and our other drug candidates are investigational agents and continued research and development for these drug candidates is subject to substantial risks, including negative safety and efficacy findings in ongoing clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-255 and our other drug candidates are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval; (iv) the timing of the commencement or end of clinical trials and the availability of clinical data may be delayed or unsuccessful due to challenges caused by the COVID-19 pandemic, regulatory delays, slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, evolving regulatory requirements, clinical trial design, clinical outcomes, competitive factors, or delay or failure in ultimately obtaining regulatory approval in one or more important markets; (v) we may not achieve the expected costs savings we expect from the restructuring and reorganization, (vi) patents may not issue from our patent applications for our drug candidates, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required; and (vii) certain other important risks and uncertainties set forth in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 5, 2022. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Vivian Wu of Nektar Therapeutics
CONDENSED CONSOLIDATED BALANCE SHEETS
|September 30, |
|December 31, |
|Cash and cash equivalents||$||105,758||$||25,218|
|Other current assets||22,507||23,333|
|Total current assets||599,483||795,581|
|Property, plant and equipment, net||36,803||60,510|
|Operating lease right-of-use assets||65,896||117,025|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accrued clinical trial expenses||20,461||26,809|
|Other accrued expenses||15,299||15,468|
|Operating lease liabilities, current portion||18,508||17,441|
|Total current liabilities||83,989||85,200|
|Operating lease liabilities, less current portion||116,145||125,736|
|Development derivative liability||-||27,726|
|Liabilities related to the sales of future royalties, net||165,595||195,427|
|Other long-term liabilities||3,054||3,592|
|Commitments and contingencies|
|Capital in excess of par value||3,561,878||3,516,641|
|Accumulated other comprehensive loss||(8,169||)||(4,157||)|
|Total stockholders’ equity||412,223||679,508|
|Total liabilities and stockholders’ equity||$||781,006||$||1,117,189|
|The consolidated balance sheet at December 31, 2021 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements.|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share information)
|Three months ended |
|Nine months ended |
|Non-cash royalty revenue related to the sales of future royalties||18,342||19,413||52,167||58,667|
|License, collaboration and other revenue||314||314||1,896||396|
|Operating costs and expenses:|
|Cost of goods sold||4,972||5,311||15,402||18,734|
|Research and development||33,590||103,738||183,583||300,655|
|General and administrative||22,534||29,468||70,394||90,702|
|Restructuring, impairment and other costs of terminated program||16,830||-||124,350||-|
|Total operating costs and expenses||77,926||138,517||393,729||410,091|
|Loss from operations||(54,301||)||(113,596||)||(323,697||)||(333,193||)|
|Non-operating income (expense):|
|Change in fair value of development derivative liability||-||(3,328||)||33,427||(7,640||)|
|Non-cash interest expense on liabilities related to the sales of future royalties||(6,953||)||(12,801||)||(21,710||)||(39,186||)|
|Interest income and other income (expense), net||2,050||131||3,541||2,388|
|Total non-operating income (expense), net||(4,903||)||(15,998||)||15,258||(44,438||)|
|Loss before provision for income taxes||(59,204||)||(129,594||)||(308,439||)||(377,631||)|
|Provision (benefit) for income taxes||(155||)||112||71||561|
|Basic and diluted net loss per share||$||(0.31||)||$||(0.70||)||$||(1.65||)||$||(2.07||)|
|Weighted average shares outstanding used in computing basic and diluted net loss per share||187,641||184,110||186,767||182,736|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
|Nine months ended |
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Non-cash royalty revenue related to the sales of future royalties||(52,167||)||(58,667||)|
|Non-cash interest expense on liabilities related to the sales of future royalties||21,710||39,186|
|Change in fair value of development derivative liability||(33,427||)||7,640|
|Non-cash research and development expense||4,951||11,497|
|Depreciation and amortization||9,848||10,710|
|Impairment of right-of-use assets and property, plant and equipment||58,521||-|
|Amortization of premiums (discounts), net and other non-cash transactions||(372||)||5,677|
|Changes in operating assets and liabilities:|
|Operating leases, net||(1,423||)||2,932|
|Other accrued expenses||(7,055||)||(4,442||)|
|Net cash used in operating activities||(246,304||)||(261,122||)|
|Cash flows from investing activities:|
|Purchases of investments||(295,439||)||(816,049||)|
|Maturities of investments||626,424||902,687|
|Sales of investments||-||5,035|
|Purchases of property, plant and equipment||(5,164||)||(9,093||)|
|Net cash provided by investing activities||325,821||82,580|
|Cash flows from financing activities:|
|Proceeds from shares issued under equity compensation plans||655||31,436|
|Cash receipts from development derivative liability||750||2,250|
|Net cash provided by financing activities||1,405||33,686|
|Effect of foreign exchange rates on cash and cash equivalents||(382||)||(82||)|
|Net increase (decrease) in cash and cash equivalents||80,540||(144,938||)|
|Cash and cash equivalents at beginning of period||25,218||198,955|
|Cash and cash equivalents at end of period||$||105,758||$||54,017|
|Supplemental disclosure of cash flow information:|
|Operating lease right-of-use assets recognized in exchange for lease liabilities||$||-||$||1,057|